AbangeLabs6d ago
Trial retention is now an HTA evidence-governance issue: missing outcomes can weaken comparative estimates, utility inputs, and reimbursement models. https://www.mattheneus.com/editorial/trial-retention-outcome-data-completeness-hta-evidence-governance-playbook-2026-04-22 #HTA #NMA #MAIC #EvidenceSynthesis #RegulatoryAffairs
Trial retention and outcome-data completeness now need a dedicated HTA governance plan

A 20 April 2026 BMJ Open synthesis of participant reasons for trial non-completion turns retention into a concrete evidence-design problem for health technology assessment. When outcome data go missing, comparative estimates, utility inputs, and reimbursement models all become harder to defend.

AbangeLabs Editorial
DoomsdaysCWApr 30

HAPPENING NOW!

#LakotaYouths are Locked Down to #Drilling Equipment at #PeSla

Drilling is Shut Down Now at 1 P.M. on Thursday: Two Drilling Sites are Shut Down and All Workers Were Sent Home. Lakota Youths Protecting Their Water Demand that all Drilling be Halted Until this is Heard in Court on Monday.

Posted by #NDNCollective, April 30, 2026, via @bsnorrell.blogspot.com

Photos by Angel White Eyes

"Lakota youth have locked down onto the drilling equipment at Pe’ Sla. An alter has been set up and community members have offered prayers. The drilling company said that law enforcement is on the way.

"At this time, we are calling on Tribes, Nations, Organizations, Collectives, and Coalitions to show support and sign the 'Stop the Drilling at Pe’ Sla' sign-on letter:

"If you are nearby, we encourage you to visit the #MysticRanger station and tell them to Rescind the permit and stop the drilling at Pe' Sla.

"#Mining activity is currently taking place at Pe' Sla despite community opposition. The Rochford Mineral Exploratory Drilling Project (#RMEDP) which seeks to drill for graphite, proposed by #PeteLien & Sons, must be stopped.

"The 2026 #MMIR March is a collaborative effort between the Minnesota Indian Women’s Sexual Assault Coalition (#MIWSAC), the Minneapolis American Indian Center (#MAIC), the Minnesota Indian Women’s Resource Center (#MIWRC), the Indian Health Board of Minneapolis, the Native American Community Development Institute (#NACDI), the Minnesota Missing and Murdered Indigenous Relatives (#MMIR) Office, #GatheringsCafe, #Minneapolis Public Schools American Indian Education, the #IndigenousProtectors Movement, the #TRADISH Project (a MAIC program), the Culture Language Arts Network (a MAIC program), Indigenous Women’s Life Net (a MAIC Program), the Many Shields Society, Mending the Sacred Hoop, Make Voting a Tradition (a NACDI program), and the #AmericanIndianMovement (AIM)."

Source [includes photos]:
https://bsnorrell.blogspot.com/2026/04/lakota-youths-are-locked-down-to.html

Sign on letter:
https://ndnco.cc/signtosavepesla

#USPol #IndigenousNews #IndigenousResistance #ProtectTheSacred #BlackHills #NoMining #OcetiSakowin #SiouxNation #PLS #RapidCreekWatershed

Lakota Youths are Locked Down to Drilling Equipment at Pe'Sla

Censored News is a service to grassroots Indigenous Peoples engaged in resistance and upholding human rights.

AbangeLabsApr 2
HTA evidence teams are hitting a fragmentation wall: ITC, MAIC, NMA, RWE, modelling, and reporting now need one traceable workflow, not stitched-together handoffs. https://www.mattheneus.com/editorial/abangelabs-hta-studio-itc-foundation-end-to-end-hta-evidence-platform-2026-04-02 #HTA #NMA #MAIC #EvidenceSynthesis #HealthEconomics
AbangeLabs HTA Studio: From ITC Foundation to End-to-End HTA Evidence Platform

Health technology assessment (HTA) evidence teams are increasingly asked to deliver multi-method evidence packages spanning indirect treatment comparison (ITC), matching-adjusted indirect comparison (MAIC), network meta-analysis (NMA), economic modelling, and reporting. This article examines why fragmented execution is becoming a methodological governance risk and how AbangeLabs HTA Studio addresses that problem through documented current capabilities.

AbangeLabs Editorial
AbangeLabsApr 2
G-BA says concizumab's added benefit is not proven in haemophilia A because comparator alignment still decides whether evidence lands or unravels. https://www.mattheneus.com/editorial/g-ba-concizumab-haemophilia-a-added-benefit-not-proven-comparator-mismatch-2026-04-02 #HTA #NMA #MAIC #EvidenceSynthesis
German Federal Joint Committee (G-BA) says concizumab added benefit is not proven in haemophilia A

On 19 March 2026, the German Federal Joint Committee (G-BA) concluded that concizumab added benefit is not proven for routine prophylaxis of bleeding in people aged 12 years and older with severe haemophilia A and no factor VIII inhibitors. The core issue was evidence architecture, not a failed positive trial: the submitted package did not provide a relevant comparison against factor VIII prophylaxis or emicizumab, and no accepted indirect treatment comparison supported the claim.

AbangeLabs Editorial
AbangeLabsApr 2
NICE’s fezolinetant decision is a live case study in how reimbursement can clear despite uncertain indirect evidence beyond placebo. The real lesson is comparator-bridge discipline, not false certainty. https://www.mattheneus.com/editorial/nice-fezolinetant-menopause-final-guidance-indirect-comparison-uncertainty-2026-04-02 #HTA #NMA #MAIC #EvidenceSynthesis #RegulatoryAffairs
National Institute for Health and Care Excellence (NICE) clears fezolinetant when hormone replacement therapy is unsuitable

On 31 March 2026, the National Institute for Health and Care Excellence (NICE) published final guidance TA1143 recommending fezolinetant for moderate to severe vasomotor symptoms associated with menopause when hormone replacement therapy is unsuitable.

AbangeLabs Editorial
AbangeLabsMar 31
Single-arm evidence can price in uncertainty unless HTA assumptions are explicitly governed. https://www.mattheneus.com/editorial/gene-therapy-single-arm-hta-economic-evidence-playbook-2026-03-27 #HTA #MAIC #HealthEconomics #RegulatoryAffairs
Single-Arm Evidence and Economic Extrapolation for Gene Therapies: A Cross-HTA Governance Playbook

Two FDA approvals for ultra-rare disease gene therapies in March 2026 crystallise a structural challenge that spans every major HTA jurisdiction: regulatory approval on single-arm evidence does not generate the comparative data that HTA bodies require.

AbangeLabs Editorial
AbangeLabsMar 30

HAS France NMA Acceptability Framework: A Cross-Agency Evidence Planning Playbook.

https://www.mattheneus.com/editorial/fallback-canary-has-france-nma-acceptability-framework-evidence-planning-playbook-2026-03-27

#HTA #NMA #MAIC #RegulatoryAffairs #EvidenceSynthesis

HAS France NMA Acceptability Framework: A Cross-Agency Evidence Planning Playbook

France's Haute Autorité de Santé (HAS) publishes explicit validity conditions for indirect treatment comparison (ITC) evidence that diverge from the binary RCT-only stance historically associated with German AMNOG. Understanding these conditions — and how they intersect with IQWiG and NICE methodology — is one of the highest-leverage planning activities a global evidence team can perform. This playbook maps the HAS acceptability framework for network meta-analysis (NMA) evidence, compares it…

AbangeLabs Editorial
AbangeLabsMar 30

Bridging HAS and IQWiG Evidence Standards: A Cross-Border Network Meta-Analysis Planning Playbook.

https://www.mattheneus.com/editorial/fallback-canary-has-iqwig-cross-border-nma-evidence-planning-playbook-2026-03-26

#HTA #NMA #MAIC #RegulatoryAffairs #EvidenceSynthesis

Bridging HAS and IQWiG Evidence Standards: A Cross-Border Network Meta-Analysis Planning Playbook

France and Germany impose distinct but reconcilable methodological requirements on indirect treatment comparison evidence. This playbook maps the divergences between HAS and IQWiG and provides an actionable architecture for building a single NMA and MAIC evidence package that satisfies both national agencies — reducing submission rework and eliminating cross-dossier inconsistency risk.

AbangeLabs Editorial
AbangeLabsMar 30

MHRA's patient-information modernisation and device advice refresh set a new evidence-operations baseline.

https://www.mattheneus.com/editorial/mhra-improving-patient-information-device-regulatory-advice-evidence-operations-playbook-2026-03-19

#HTA #NMA #MAIC #RegulatoryAffairs #EvidenceSynthesis

MHRA's patient-information modernisation and device advice refresh set a new evidence-operations baseline

MHRA updates published between 12 and 18 March 2026 indicate a tighter operational cadence for patient information and medical device regulatory advice. This playbook translates those signals into concrete evidence-governance actions for HTA and market access teams.

AbangeLabs Editorial
AbangeLabsMar 30

EMA Management Board ePI roadmap turns product-information governance into an HTA evidence operations priority.

https://www.mattheneus.com/editorial/ema-management-board-epi-roadmap-evidence-operations-playbook-2026-03-14

#HTA #NMA #MAIC #RegulatoryAffairs #EvidenceSynthesis

EMA Management Board ePI roadmap turns product-information governance into an HTA evidence operations priority

EMA Management Board updates on 13 March 2026 position electronic product information and implementation governance as immediate evidence-operations triggers. This playbook shows how decision teams can operationalise change detection, ITC assumption control, and auditable rerun logic.

AbangeLabs Editorial